The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
Open accessAbstract
There is no standard treatment for patients with unresectable hepatocellular carcinoma (HCC). Survival benefits derived from medical interventions are controversial. The aim of this systematic review was to assess the evidence of the impact of medical treatments on survival. Randomized controlled trials (RCTs) that were published as full papers assessing survival for primary treatments of HCC were included. MEDLINE, the Cochrane Library, CANCERLIT, and a manual search from 1978 to May 2002 were used. The primary end point was survival, and the secondary end point was response to treatment. Estimates of effect were calculated according to the random effects model. Sensitivity analysis included methodological quality. We identified 61 randomized trials, but only 14 met the criteria to perform a meta-analysis assessing arterial embolization (7 trials, 545 patients) or tamoxifen (7 trials, 898 patients). Arterial embolization improved 2-year survival compared with control (odds ratio [OR], 0.53; 95% confidence interval [CI], 0.32-0.89; P = .017). Sensitivity analysis showed a significant benefit of chemoembolization with cisplatin or doxorubicin (OR, 0.42; 95% CI, 0.20-0.88) but none with embolization alone (OR, 0.59; 95% CI, 0.29-1.20). Overall, treatment induced objective responses in 35% of patients (range, 16%-61%). Tamoxifen showed no antitumoral effect and no survival benefits (OR, 0.64; 95% CI, 0.36-1.13; P = .13), and only low-quality scale trials suggested 1-year improvement in survival. In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04149-5 · Cited by 4,826
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationPrognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Self-citationEstimating the world cancer burden: Globocan 2000
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001) · International Journal of Cancer · doi:10.1002/ijc.1440 · Cited by 3,721
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationImproving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Lo, C.-M., Ngan, H., Tso, W.-K., Liu, C.-L., Lam, C.-M., Poon, R. T.-P., Fan, S.-T., & Wong, J. (2002) · Hepatology · doi:10.1053/jhep.2002.33156 · Cited by 2,613
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Kjaergard, L. L., Villumsen, J., & Gluud, C. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-11-200112040-00010 · Cited by 2,283
Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions
Cook, D. J., Mulrow, C. D., & Haynes, R. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-5-199703010-00006 · Cited by 2,184
A prospective randomized trial
(1995) · Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons) · doi:10.4030/jjcs1979.20.2_191 · Cited by 1,619
meta-analysis bias in location and selection of studies
Egger, M., & Smith, G. D. (1998) · BMJ · doi:10.1136/bmj.316.7124.61 · Cited by 1,374
A double‐blind, placebo‐controlled trial
Pinals, R. S., Kaplan, S. B., Lawson, J. G., & Hepburn, B. (1986) · Arthritis & Rheumatism · doi:10.1002/art.1780291202 · Cited by 1,355
Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J. (1999) · Hepatology · doi:10.1002/hep.510290145 · Cited by 1,190
Self-citationPrognostic prediction and treatment strategy in hepatocellular carcinoma
Bruix, J., & Llovet, J. M. (2002) · Hepatology · doi:10.1053/jhep.2002.32089 · Cited by 1,099
Self-citationCammà, C., Schepis, F., Orlando, A., Albanese, M., Shahied, L., Trevisani, F., Andreone, P., Craxì, A., & Cottone, M. (2002) · Radiology · doi:10.1148/radiol.2241011262 · Cited by 851
(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Cha, M., Eastwaad, S., Hartan, R., Maher, D., Olkin, I., Pitkin, R., Rennie, D., Schulz, K. F., Simel, D. L., & Straup, D. F. (1996) · Cited by 737
Shibata, T., Iimuro, Y., Yamamoto, Y., Maetani, Y., Ametani, F., Itoh, K., & Konishi, J. (2002) · Radiology · doi:10.1148/radiol.2232010775 · Cited by 575
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Self-citationWhat contributions do languages other than English make on the results of meta-analyses?
Moher, D., Pham, Klassen, T. P., Schulz, K. F., Berlin, J. A., Jadad, A. R., & Liberati, A. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00188-8 · Cited by 453
Overcoming the limitations of current meta-analysis of randomised controlled trials
Pogue, J., & Yusuf, S. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08461-4 · Cited by 428
Pelletier, G., Roche, A., Ink, O., Anciaux, M. L., Derhy, S., Rougier, P., Lenoir, C., Attali, P., & Etienne, J.-P. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90110-d · Cited by 417
Pogue, J. M., & Yusuf, S. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00051-2 · Cited by 415
Pelletier, G., Ducreux, M., Gay, F., Luboinski, M., Hagège, H., Thong, D., Van Steenbergen, W., Buffet, C., Rougier, P., Adler, M., et al. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80187-6 · Cited by 396
Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
Simonetti, R. G., Liberati, A., Angiolini, C., & Pagliaro, L. (1997) · Annals of Oncology · doi:10.1023/a:1008285123736 · Cited by 380
Bañares, R., Albillos, A., Rincón, D., Alonso, S., González, M., Ruiz-del-Arbol, L., Salcedo, M., & Molinero, L.-M. (2002) · Hepatology · doi:10.1053/jhep.2002.31354 · Cited by 364
Kawata, S., Yamasaki, E., Nagase, T., Inui, Y., Ito, N., Matsuda, Y., Inada, M., Tamura, S., Noda, S., Imai, Y., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1716 · Cited by 354
Lin, D.-Y., Liaw, Y.-F., Lee, T.-Y., & Lai, C.-M. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90436-2 · Cited by 294
Raoul, J., Guyader, D., Bretagne, J., Heautot, J., Duvauferrier, R., Bourguet, P., Bekhechi, D., Deugnier, Y. M., & Gosselin, M. (1997) · Hepatology · doi:10.1002/hep.510260511 · Cited by 286
Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study
Kouroumalis, E., Skordilis, P., Thermos, K., Vasilaki, A., Moschandrea, J., & Manousos, O. N. (1998) · Gut · doi:10.1136/gut.42.3.442 · Cited by 280
Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
Llovet, J. M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodés, J., & Bruix, J. (2000) · Hepatology · doi:10.1002/hep.510310111 · Cited by 271
Self-citationIssues in Comparisons Between Meta-analyses and Large Trials
Ioannidis, J. P. A. (1998) · JAMA · doi:10.1001/jama.279.14.1089 · Cited by 253
Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Lai, C.-L., Lau, J. Y. N., Wu, P.-C., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., Chow, A. W. C., & Lin, H.-J. (1993) · Hepatology · doi:10.1002/hep.1840170307 · Cited by 221
Ohnishi, K., Yoshioka, H., Ito, S., & Fujiwara, K. (1998) · Hepatology · doi:10.1002/hep.510270112 · Cited by 216
Chow, P. K. H., Tai, B.-C., Tan, C.-K., Machin, D., Win, K. M., Johnson, P. J., & Soo, K.-C. (2002) · Hepatology · doi:10.1053/jhep.2002.36824 · Cited by 209
Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial
(1998) · The Lancet · doi:10.1016/s0140-6736(98)01259-8 · Cited by 202
Castells, A., Bruix, J., Brú, C., Ayuso, C., Roca, M., Boix, L., Vilana, R., & Rodés, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90402-6 · Cited by 187
Self-citationMathurin, Rixe, Carbonell, Bernard, Cluzel, Bellin, Khayat, Opolon, & Poynard (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00286.x · Cited by 164
Grimaldi, C. H., Bleiberg, H., Gay, F., Messner, M., Rougier, P. R., Kok, T. C., Cirera, L., Cervantes, A. M. R., Grève, J. D., Paillot, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.411 · Cited by 132
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma
Habib, N. A., Salama, H., Median, A. A. E. L. A., et al. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700431 · Cited by 127
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
Martínez-Cerezo, F. J., Tomás, A., Donoso, L., Enríquez, J., Guarner, C., Balanzó, J., Martínez‐Noguera, A., & Vilardell, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80138-2 · Cited by 126
Eastern Cooperative Oncology Group (ECOG).
Fairclough, D. L., & Cella, D. F. (1996) · PubMed · Cited by 109
Villa, E., Ferretti, I., Grottola, A., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1534 · Cited by 96
Liu, C.-L., Fan, S.-T., Ng, I. O., et al. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01688.x · Cited by 93
A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: An RTOG study
Order, S. E., Pajak, T. J., Leib, S., et al. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90191-6 · Cited by 54
Kajanti, M. J., Pyrhönen, S. O., Mäntylä, M., & Rissanen, P. M. (1992) · American Journal of Clinical Oncology · doi:10.1097/00000421-199202000-00008 · Cited by 43
Falkson, G., Cnaan, A., SIMSON, I. W., Dayal, Y., Falkson, H. C., Smith, T. J., & Haller, D. G. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199012000-00012 · Cited by 42
Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
Falkson, G., MacIntyre, J. M., Schutt, A. J., Coetzer, B., Johnson, L. A., Simson, I. W., & Douglass, H. O. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.6.581 · Cited by 42
Treatment of unresectable hepatocellular carcinoma : Results of a randomized controlled trial
Lai, E. C. S., Tong, T. R. S.-W., Ong, G. B., et al. (1986) · World Journal of Surgery · doi:10.1007/bf01655321 · Cited by 39
van der Merwe, C. F., Booyens, J., Joubert, H. F., & Merwe, C. A. V. D. (1990) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/0952-3278(90)90098-6 · Cited by 37
Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
(2000) · Pure Amsterdam UMC · doi:10.1002/(sici)1097-0142(20000501)88:9
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationForner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Self-citation
Metadata
- Authors
- Llovet, J. M., & Bruix, J.
- Venue
- Hepatology
- Published
- 2003-02
- Volume
- 37
- Issue
- 2
- Pages
- 429-442
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1975154077
- Cited by
- 3,029
- References
- 57
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.